IRIS announced the launch of a new AI-driven document management solution built specifically for CPAs that, among other things, automates tagging and filing for users.
Debtor-in-process financing up to $55 million could keep the lights on at Karyopharm Therapeutics for its multiple myeloma and myelofibrosis programs as the biotech waits to see if its union with Ayrmid will go through.
In a mid-stage trial, the lower dose of Tiziana’s intranasal monoclonal antibody reduced microglial activation in a specific type of multiple sclerosis. But the path forward remains unclear after the higher dose failed to deliver the same benefit.
Sail Biomedicine’s $925 million deal with Johnson & Johnson helped boost the cell and gene therapy sector over biologics in terms of venture capital fundraising in the third quarter.